Recursion Pharmaceuticals Inc - Class A

NASDAQ: RXRX
$7.24
-$0.45 (-5.9%)
Closing Price on January 31, 2025

RXRX Stock Chart and Intraday Price

RXRX Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 41S RIO GRANDE STREET, SALT LAKE CITY, UT, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 2,765.35M USD
Shares Outstanding 208,284,000
Recursion Pharmaceuticals Inc is a trailblazer in the biotech industry, focusing on revolutionizing drug discovery by merging advancements in biology, chemistry, automation, data science, and engineering. With a robust pipeline of drugs in various clinical trial stages, including treatments for cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, Clostridioides difficile infection, and certain cancers, Recursion is at the forefront of developing innovative therapies. Founded in 2013 and based in Salt Lake City, Utah, the company collaborates with leading entities like Bayer AG and Takeda Pharmaceutical to push the boundaries of medical research.

RXRX Articles

Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns. Notably,...
Investors either love Cathie Wood or hate her. The founder of the Ark Invest family of exchange-traded funds can either be phenomenally successful or a dismal failure.  While Wood formed her...
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.